Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Autism Clear all
Completed Phase 3 Interventional

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions
Cariprazine Flexible Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 8, 2026, 5:36 PM EDT
Recruiting Phase 3 Interventional

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

NCT06229210
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Comparison Between a Live Canine or Toy Dog on Prosocial Behavior and Emotional Regulation in Autistic Children

NCT06915415
View directory record Official record
Conditions
Prosocial Behavior, Emotional Regulation, Human Animal Bonding, Human Animal Interaction, Autism
Interventions
Animal-assisted therapy, Behavioral therapy
Behavioral
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
3 Years to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 8, 2026, 5:36 PM EDT
Recruiting No phase listed Observational

Patterns of Neurodevelopmental Disorders

NCT06213090
View directory record Official record
Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions
Not listed
Lead sponsor
Richard Frye
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Recruiting Phase 3 Interventional

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

NCT06690398
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Lumateperone high dose, Lumateperone low dose, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
35
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance

NCT03002363
View directory record Official record
Conditions
Autism
Interventions
Video Modeling Intervention, Placebo Video
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Months to 36 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Pediatric Aquatic Occupational Therapy for Children With Sensory Processing Challenges

NCT06484946
View directory record Official record
Conditions
Sensory Processing Disorder, Autism Spectrum Disorder, ADHD
Interventions
aquatic occupational therapy
Other
Lead sponsor
Kristen Pataki
Other
Eligibility
4 Years to 9 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seven Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Pediatric Early Autism Recognition System: PEARS

NCT05153551
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Play-based assessment (RITA-T)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Months and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Brighton, Michigan • Northville, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 8, 2026, 5:36 PM EDT
Completed No phase listed Observational

A Repeatability and Reproducibility Study of the EarliPoint™ Device

NCT04860986
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
EarliPoint
Device
Lead sponsor
EarliTec Diagnostics, Inc
Industry
Eligibility
16 Months to 30 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 8, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

The Family VOICE Study

NCT01804582
View directory record Official record
Conditions
Autism, Aggression, Bipolar Disorder, Psychotic Disorders
Interventions
Family Navigator consultation
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Years to 15 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 8, 2026, 5:36 PM EDT
Recruiting No phase listed Observational

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

NCT07493096
View directory record Official record
Conditions
Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities, Developmental Delay (Disorder), Cerebral Palsy (CP), Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment, Cerebral Palsy Infantile, Cerebral Palsy Spastic Hemiplegic, Cerebral Palsy, Dyskinetic, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD, Hypoxic Ischemic Encephalopathy, Hypoxic Ischemic Encephalopathy (HIE), Traumatic Brain Injury (TBI), Sensory Processing Disorder, Chromosomal Abnormalities, Genetic Disorders, Down Syndrome (Trisomy 21), Fragile X Syndrome (FXS), RETT Syndrome With Proven MECP2 Mutation, Williams Syndrome, 22q11.2 Deletion Syndrome, Sensorimotor Integration
Interventions
Not listed
Lead sponsor
Healing Hope International
Other
Eligibility
4 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
View directory record Official record
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

NCT06557902
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Lumateperone 10.5 mg capsule, Lumateperone 21 mg capsule, Lumateperone 5 mg ODT, Lumateperone 10.5 mg ODT, Lumateperone 15.5 mg ODT, Lumateperone 21 mg ODT
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Orlando, Florida • Atlanta, Georgia • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study

NCT01506232
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 8, 2026, 5:36 PM EDT
Recruiting Phase 3 Interventional

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

NCT06706674
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Lumateperone high dose, Lumateperone low dose, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Little Rock, Arkansas • Sacramento, California • Sherman Oaks, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Family, Responsibility, Education, Support, and Health for Families With a Child With Autism

NCT05741840
View directory record Official record
Conditions
Autism Spectrum Disorder, Obesity, Childhood, Autism
Interventions
PBT-A, Health Education (HE)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
6 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities

NCT03218462
View directory record Official record
Conditions
Developmental Disability, Intellectual Disability, Dental Anxiety
Interventions
Sensory Adapted Dental Environment (SADE)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 8, 2026, 5:36 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Gut Microbiome and Its Association With Pediatric Stress and Cognition

NCT06269614
View directory record Official record
Conditions
Autism Spectrum Disorder, Adverse Childhood Experiences, Stress Reaction
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Nova Southeastern University
Other
Eligibility
4 Years to 95 Months
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

NCT01592747
View directory record Official record
Conditions
Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl), Placebo capsules
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
64
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions
Risperidone, Other atypical antipsychotic drugs
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
8 Years to 16 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Sep 8, 2026, 5:36 PM EDT
Completed Not applicable Interventional

Use of an Adaptive Sensory Environment in Autism Spectrum Disorder (ASD) Patients in the Perioperative Environment

NCT04994613
View directory record Official record
Conditions
Autism Spectrum Disorder, Anesthesia, Procedural Anxiety, Sensory Processing Disorder
Interventions
Sensory adaptive environment
Other
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
3 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 8, 2026, 5:36 PM EDT
Active, not recruiting Phase 3 Interventional

An Open Label Study of CM-AT for the Treatment of Children With Autism

NCT02649959
View directory record Official record
Conditions
Autism
Interventions
CM-AT
Drug
Lead sponsor
Curemark
Industry
Eligibility
3 Years to 17 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 8, 2026, 5:36 PM EDT